Invasive tumors, including gliomas, utilize proteinases to degrade extracellular matrix components and diffuse into the adjacent tissues or migrate toward distant ones. In addition, proteinase activity is required for the formation of new blood vessels within the tumor. Levels of the proteinase matrix metalloproteinase-2 (MMP-2) are highly increased in gliomas. In this study, we examined the effect of the downregulation of MMP-2 via adenovirus-mediated siRNA in gliomas. Here, we show that siRNA delivery significantly decreased levels of MMP-2 in the glioblastoma cell lines U-87 and U-251. U-87 and U-251 cells showed impaired invasion through matrigel as well as decreased migration from tumor spheroids transfected with adenoviral vector expressing siRNA against MMP-2. Additionally, tumor-induced angiogenesis was decreased in in vitro experiments in cultured human microvascular endothelial cells (HMECs) in serum-free conditioned medium of glioblastoma cells transfected with these constructs and co-cultures of glioma cells with HMECs. We also observed decreased angiogenesis in the in vivo dorsal skin-fold chamber model. Moreover, MMP-2 inhibition induced apoptotic cell death in vitro, and suppressed tumor growth of preestablished U-251 intracranial xenografts in nude mice. Thus, specific targeting of MMP-2 may provide a novel, efficient approach for the treatment of gliomas and improve the poor outcomes of patients with these brain tumors.
Introduction
Gliomas are the most common central nervous system tumors in adults. Glioblastoma multiforme, a grade IV glioma (World Health Organization), is the most aggressive brain tumor. Patients with glioblastoma multiforme typically have a poor prognosis, even after aggressive surgery, radiation and advanced chemotherapy. Completely removing the tumor surgically is nearly impossible because of the diffusive growth pattern of gliomas. The mean survival time after initial diagnosis is approximately 6-12 months with current therapies being unable to improve the poor outcome (Castro et al., 2003) . Previous research indicates that these tumors have a tendency to recur soon after resection of the initial tumor mass. This phenomenon is indicative of the highly invasive capacity of gliomas, and is what allows tumor cells to spread into normal brain tissue (Giese and Westphal, 1996) . Tumor cells manage to obtain these invasive properties primarily because of their ability to secrete and activate proteolytic enzymes, such as serine, metallo-and cysteine proteases, which are capable of degrading extracellular matrix (ECM) components and breaking down other natural barriers to tumor invasion (Rao, 2003) .
Matrix metalloproteinases (MMPs) constitute a family of secreted, zinc-dependent endopeptidases that are required for ECM degradation in a variety of physiological and pathological tissue remodeling processes, including wound healing, embryo implantation, tumor invasion, metastasis and angiogenesis (Stetler-Stevenson, 1990; Woessner and Gunja-Smith, 1991; Ray and Stetler-Stevenson, 1994; Rosenberg, 1995) . MMP-2, a 72 kD gelatinase, degrades nonfibrillar and denatured collagens, and is secreted as a latent pro-form that is processed into the active molecule through interaction with membrane type 1-MMP (MT1-MMP) on the cell surface, and the interaction regulated by tissue inhibitor of MMP-2 (Deryugina et al., 1998) . MMP-2 is highly expressed in gliomas as compared to normal brain tissue, and both mRNA and protein levels increase along with tumor progression and grade. It has been shown that MMP-2 is localized in both tumor and vasculature cells, indicating multiple roles for this molecule in tumor progression, including angiogenesis (Sawaya et al., 1996; Forsyth et al., 1999) . MMP-2 expression is also known to associate with tumor invasion, angiogenesis, metastasis and recurrence (Wang et al., 2003; Chambers and Matrisian, 1997, Komatsu et al., 2004) .
In the present study, we take advantage of the RNA interference (RNAi) approach, by using an adenoviral construct in order to deliver small interfering RNA molecules that target MMP-2 mRNA. RNAi is an efficient and specific, gene silencing mechanism, which occurs at a post-transcriptional level. Here we show that adenovirus mediated transfer of siRNA against MMP-2 inhibits invasion and tumor-induced angiogenesis of glioblastoma cell lines U-87 and U-251, induces apoptotic cell death, as well as causes regression of preestablished intracranial tumors of U-251 cells.
Results

Ad-MMP-2 downregulates MMP-2 protein and activity
To test the efficacy of adenoviral vector expressing siRNA against MMP-2 (Ad-MMP-2) in downregulating MMP-2, we infected U-87 and U-251 cells with 10, 25, 50 and 100 multiplicities of infection (MOIs) of Ad-MMP-2 (cells infected with mock or 100 MOIs of Ad-SV were used as controls). We performed gelatin zymography using conditioned media from the cultured cells to determine MMP-2 protein activity. The corresponding 72 kD proteolytic band was less intense in the cells treated with Ad-MMP-2, and was almost undetectable in the cells treated with 100 MOIs of Ad-MMP-2 construct, thereby indicating dose-dependent inhibition of MMP-2 ( Figure 1a ). We performed western blot analysis to confirm the efficient inhibition of MMP-2 by the constructs. MMP-2 protein levels were significantly decreased from conditioned media or from cell lysates in a dose-dependent manner with Ad-MMP-2 compared to mock and Ad-SV infected cells (Figure 1b) . Observation under fluorescent microscope showed that cells treated with Ad-MMP-2 siRNA had reduced signal as compared to control and Ad-SV-infected cells (Figure 1c ). The results demonstrate a dose-dependent inhibition of MMP-2 in U-87 and U-251 cells infected with various MOIs of Ad-MMP-2. Moreover, determination of cell growth with MTT assay revealed that treated with Ad-MMP-2, cells remained viable during the time course used in the in vitro experiments and that cell growth was reduced in the Ad-MMP-2 infected cells compared to mock and Ad-SV infected ones (Figure 1d ). The specificity of this adenoviral construct to selectively inhibit MMP-2 expression in U-87 and U-251 cells is shown in Supplementary Figure 1 .
Ad-MMP-2 inhibits glioma cell invasion
The ability of glioma cells to invade adjacent areas by degrading ECM components and diffusing into normal brain tissue presents a remarkable obstacle for current therapies. Because prior research indicates that MMP-2 is a critical proteinase involved in the regulation and promotion of glioma cell invasion, we studied the effect of Ad-MMP-2 on this process. Matrigel invasion assay showed a dose-dependent inhibition of tumor cell invasion (Figure 2a ) after treatment with Ad-MMP-2. The normalization of the values as percentage of the control (100%), cells treated with 50 MOIs of Ad-MMP-2 displayed 80% inhibition and those treated with 100 MOIs of Ad-MMP-2 showed a more than 90% inhibition (Figure 2b ).
Ad-MMP-2 reduces migrating capacity of glioma cells
MMPs are known to participate in tumor cell migration, at least by degrading the ECM molecules and by cleaving and releasing factors that enhance migration. Since tumor spheroids mimic tumor growth, we allowed U-87 or U-251 cells to form spheroids, and we then infected cells with Ad-MMP-2, Ad-SV or mock. We observed a significant reduction in the migrating potency of cells infected with Ad-MMP-2 as compared to the controls (Figure 2c ). However, we did not observe a significant difference in the migrating distances of spheroids (around 50 and 75%) treated with 50 and 100 MOIs of Ad-MMP-2 (Figure 2d ).
Ad-MMP-2 inhibits expression of VEGF and tumor-induced angiogenesis in vitro and in vivo Glioblastoma is one of the most highly angiogenic tumors; MMP-2 is an important angiogenic molecule that gliomas utilize to extend tumor vascularization. Our studies on tumor-induced angiogenesis in vitro show significant inhibition of the angiogenic process by Ad-MMP-2 treatment. Conditioned media from Ad-MMP-2-treated U-87 or U-251 cells failed to induce capillary-like formation when added to cultured human microvascular endothelial cells (HMECs) in contrast with the conditioned media obtained from control and Ad-SV-infected cells, which was capable of triggering the angiogenic process (Figure 3a) . Similarly, U-87 or U-251 cells infected with Ad-MMP-2 displayed a significantly inhibited capillary-like formation when co-cultured with HMECs, whereas mock and Ad-SVinfected cells efficiently induced capillary-like network formation (Figure 3b ). To quantify this effect, we measured the branch points in each field and expressed the result as percentage of the controls (mock infected), which represents the 100% angiogenic response (Figure 3c ). Moreover, protein levels of vascular endothelial growth factor (VEGF), a well-known inducer of angiogenesis, were reduced in cell lysates from U-87 or U-251 cells infected with 50 and 100 MOIs of Ad-MMP-2, indicating a possible association between MMP-2 and VEGF in the stimulation of angiogenic response from tumor cells (Figure 3d ). To confirm the in vitro results of angiogenesis inhibition in vivo, we utilized the dorsal window model in athymic mice. Control U-87 and Ad-SV-infected cells, when implanted through the chamber underneath the dorsal skin of the animal, resulted in the development of several newly-formed, thin and curved microvessels. In contrast, tumor-induced vasculature was less prominent in the skin of the animal when the implanted cells were infected with 50 MOIs of Ad-MMP-2 and almost absent when infected with 100 MOIs of Ad-MMP-2, thereby 
. We were also able to observe DNA fragmentation after purifying total nuclear DNA, which was electrophoretically separated on an agarose gel. Cells treated with Ad-MMP-2 underwent DNA degradation and cleavage of small fragments, which indicate apoptosis; this effect corresponded with increased MOIs of the Ad-MMP-2 ( Figure 4c ). Moreover, caspases-3, -8 and -9, which are molecules that mediate the apoptotic mechanism, were cleaved and activated as shown by western blot analysis of cell lysates ( Figure 4d ).
Inhibition of tumor growth in vivo
We have demonstrated so far that adenovirus-mediated transfer of siRNA targeting MMP-2 in glioblastoma cells effectively decreases invasion, migration, induces apoptosis in vitro and reduces angiogenesis both in vitro and in vivo. Next, we asked whether our treatment approach could interfere with tumor growth of intracranial tumor xenografts in nude mice and improve survival of the animals. For the intracerebral injections, we chose the glioblastoma cell line U-251, which forms highly invasive tumors in athymic mice, in contrast with U-87 cells that form solid and well-defined tumors. Eight days after tumors were induced, we treated the animals three times at 5-day intervals with 3 Â 10 8 plaque-forming units (PFUs) of the viruses or phosphate-buffered saline (PBS) (control). In addition, we used stably transfected U-251 cells expressing a luciferase plasmid, which enabled us to monitor tumor growth by intraperitoneally injecting D-luciferin into the animals and analyzing the signal emitted from each animal (quantified as photon counts). Over a 6-week period, we observed a remarkable, approximately 90%, inhibition of tumor growth in the animals treated with Ad-MMP-2 when compared with the controls (PBS or Ad-SV) as measured by photon counts and subsequently confirmed by hematoxylin and eosin (H&E) staining of the tumor sections (Figures 5a and b) . Control animals developed symptoms like weight loss and neurological signs before they were killed, whereas Ad-MMP-2-treated animals remained symptom-free. We did not observe any differences between animals treated with PBS or Ad-SV in terms of tumor size or symptoms. Moreover, brain sections were analyzed for expression of MMP-2, endoglin, VEGF and glial fibrillary acidic protein (GFAP) using immunohistochemistry ( Figure 5c ). Anti-GFAP antibody was used to verify the astrocytic origin of the tumor cells. Ad-MMP-2-treated cells showed inhibition of MMP-2 expression and were negative for endoglin staining, indicating the absence of new blood vessel formation, in contrast to control and Ad-SV-treated cells, in which MMP-2 expression was detected mostly at the invasive edge of the tumor and in cells surrounding the necrotic areas as well as reactive endothelial cells within and around the tumor area. Confirming the in vitro findings, VEGF was also suppressed in the animals treated with MMP-2 siRNA. 
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Thus, Ad-MMP-2 inhibited tumor growth in vivo and prolonged overall survival of the animals.
Discussion
Using the RNAi approach, we studied the effect of MMP-2 downregulation in two glioblastoma cell lines, U-87 (p53 wild type) and U-251 (p53 mutated). It has been shown that synthetic siRNA or shRNAs, transcribed in vivo from DNA templates are capable of specifically silencing the target gene (McCaffrey et al., 2002) . Moreover, adenoviral vectors carrying siRNA, when injected into the brain of transgenic mice, diminished expression of the gene of interest (Xia et al., 2002) . Thus, siRNA delivery via DNA vectors could possibly serve as a therapeutic tool in the Figure 3 Ad-matrix metalloproteinase-2 (MMP-2) infection inhibits tumor-induced angiogenesis in vitro and in vivo. (a) Conditioned media from U-87 or U-251 glioma cells that were infected with mock, 100 multiplicities of infection (MOIs) of Ad-SV or 50 and 100 MOIs of adenoviral vector expressing siRNA against MMP-2 (Ad-MMP-2) was added fresh daily to human microvascular endothelial cell (HMEC) cultures and incubated for 72 h. HMEC cells were then fixed, hematoxylin and eosin (H&E) stained and photographed. (b) U-87 and U-251 glioma cells were infected with the adenoviral constructs as described above, and co-cultured with HMEC in eightwell chamber slides for 48 h. Cells were then fixed and incubated with factor VIII antibody, and subsequently incubated with fluorescein isothiocyanate (FITC)-conjugated, anti-rabbit secondary antibody, mounted and photographed under a fluorescent microscope. (c) Angiogenic result was measured by counting the relative branch points in five different fields from three independent experiments for both, conditioned media replacement and co-culture assays and bars represent the means ± standard errors (s.e.). The asterisk (*) represents statistically different compared to mock-infected control (Po0.01). (d) Equal amounts of total protein (50 mg) from U-87 and U-251 cell lysates were analyzed by western blot using vascular endothelial growth factor (VEGF) primary antibody and anti-mouse secondary antibody. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody was used as a loading control. (e) U-87 cells were infected with mock, 100 MOIs of Ad-SV or 50 and 100 MOIs of Ad-MMP-2. Diffusion chambers containing 1 Â 10 6 cells were surgically placed underneath the dorsal skin of athymic mice, as described in 'Materials and methods'. PV, pre-existing vasculature; TN, tumor-induced vasculature.
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O Kargiotis et al development of new strategies that interfere with cancer biology and suppress tumor expansion. MMPs, along with serine and cysteine proteases play a central role in degrading ECM components (Goldbrunner et al., 1999) . In particular, MMP-2 is strongly correlated with the invasive capacity of glioma cell lines (Abe et al., 1994) . By using siRNA against MMP-2, we were able to reduce migration and inhibit invasion of glioma cells in vitro suggesting specific targeting of MMP-2 might prove a useful tool to augment radiotherapy, which still remains a prominent therapeutic approach to gliomas and eliminate tumor recurrence.
To grow beyond 1-3 mm 3 , tumors must be supplied by newly formed vessels that deliver nutrients and remove waste products (Folkman, 1990) . Highly vascularized glioblastomas use proteases to promote angiogenesis, which in turn, sustains tumor growth (Lakka et al., 2005a) . MMP inhibitors have been shown to block endothelial cell activities essential for new vessel development, including proliferation and invasion, (Murphy et al., 1993; Benelli et al., 1994) , thereby suggesting the role of MMPs in angiogenesis. Also, MMP-deficient mice display a reduced angiogenic response to tumor stimuli (Itoh et al., 1998) . Moreover, MMP-2 is shown to be necessary to facilitate the angiogenic switch in a tumor model, indicating the early involvement of the molecule in this process (Fang et al., 2000) . Our data indicating that Ad-MMP-2 infection inhibits radiation-induced capillary tube formation (Supplementary Figure 2 ) are in agreement with previous studies which demonstrate that radiation treatment increases MMP-2 levels both in vitro and in vivo in gliomas (Wild-Bode et al., 2001; Park et al., 2006) . Because a n b 3 mediates cell survival, the interaction of MMP-2 with a n b 3 integrin on the cell surface might also influence endothelial cell behavior The apoptotic result was measured by counting the percentage of cells that showed DNA staining in five different fields in each group and bars represent the means ± standard errors (s.e.). The asterisk (*) represents statistically different compared to mock-infected control (Po0.01). (c) Total nuclear DNA from cells infected with mock, 100 MOIs of Ad-SV or 25, 50 and 100 MOIs of Ad-MMP-2 was electrophoretically separated on 1% agarose gel, (d) Equal amounts of total protein (60 mg) from cell lysates were analyzed by western blot using caspases-3, -8 and -9 primary antibodies. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) served as a loading control. Stetler-Stevenson, 1999) . In addition, MMP-2 cleaves insulin-like growth factor-binding proteins, releasing insulin growth factors (Fowlkes et al., 1994) that are known to stimulate migration and tube formation by vascular endothelial cells (Nakao-Hayashi et al., 1992). Cleavage of laminin-5 by MMP-2 results in increased migration of epithelial cells (Giannelli et al., 1997) , and similarly, MMP-2 releases the entire extracellular domain of fibroblast growth factor receptor-1 (FGFR-1). FGFR1 remains capable of binding fibroblast growth factor and possibly modulates angiogenic activities (Levi et al., 1996) .
Recent studies show that MMP-2 can directly increase levels of bioactive VEGF in ovarian carcinoma cell lines (Belotti et al., 2003) . MT1-MMP, the activator of pro-MMP-2, exerted similar effects in glioma cell lines genetically engineered to produce high levels of the protein and increased the tumorigeneity of glioma xenografts (Deryugina et al., 2002) . In addition, irradiated melanoma cells displayed enhanced invasive capacity with increased MMP-2 expression, and subsequently induced VEGF protein secretion. Specific MMP-2 inhibition blocked VEGF upregulation, and inhibited tumor growth and angiogenesis in vivo (Kaliski et al., 2005) . Similarly, the results of the present study demonstrate that siRNA-induced MMP-2 inhibition decreased VEGF protein levels in glioblastoma cell lines. These data indicate the possible role of MMP-2 in regulating VEGF activity, either by interfering with cell signaling through interaction with receptors (for example, a n b 3 integrin) or via the proteolytic activity of MMP-2, which might result in cleavage of bioactive molecules or the elimination of other molecules that directly influence VEGF. Moreover, MMP-2 downregulation efficiently blocked glioma-induced angiogenesis both in vitro and in vivo, thereby highlighting the importance of the molecule as an angiogenic factor.
Recent studies have expanded the role of MMPs in tumor progression to include other aspects of tumor biology besides invasion and angiogenesis. The ability of the molecules to cleave cell-surface receptors or to activate/inactivate cytokines and growth factors implicate MMPs in cellular processes like proliferation and apoptosis (Egeblad and Werb, 2002; Lakka et al., 2005b ). In the current study, infection of the glioblastoma cell lines with the adenoviral construct carrying Figure 5 Inhibition of tumor growth in vivo. In total 1 Â 10 6 U-251 cells were injected intracerebrally into the right hemisphere of athymic mice using the guide screw system. After 8 days, animals were separated into three groups and were treated thrice at 5-day intervals with 3 Â 10 8 plaque-forming units (PFUs) of Ad-SV or Ad-matrix metalloproteinase-2 (MMP-2) diluted in 10 ml of phosphatebuffered saline (PBS) or PBS alone (mock). At 6 weeks after the experiment was initiated, animals were killed with intracardiac perfusion of PBS, followed by formaldehyde and brains were removed. (a) Before animals were killed, an intraperitonal injection of 2.5 mg D-luciferin sodium salt diluted in 50 ml of PBS was given and animals were photographed under the IVIS camera for fluorescent light emission. The signal was measured as photon counts using IVIS software. The bars represent the means±standard errors (s.e.). The asterisk (*) represents statistically different compared to mock-treated controls (Po0.01). (b) Brain sections were stained with hematoxylin and eosin (H&E), and photographed under a light microscope at Â 4 and Â 40 magnifications. (c) Immunohistochemical analysis of brain sections using anti-MMP-2, anti-endoglin, anti-vascular endothelial growth factor (VEGF) and anti-glial fibrillary acidic protein (GFAP) antibodies. Sections were photographed at a Â 60 magnification.
O Kargiotis et al siRNA against MMP-2 triggered apoptosis through the cleavage and activation of the pro-apoptotic molecules caspases-3, -8 and -9 and subsequent DNA damage. These data reveal that MMP-2 might be an important molecule that mediates survival of glioma cells and also support the multifunctional role of MMPs in tumor progression. In addition, the possible involvement of MMP-2 in the biological balance favoring cell survival and proliferation could be another way by which MMPs are implicated in the early steps of tumor evolution (Folgueras et al., 2004 ). Finally, we tested the hypothesis of whether Ad-MMP-2 treatment could block the progression of preestablished, invasive intracranial tumors arising from U-251 glioblastoma cells. Notably, after three single, intratumoral injections of Ad-MMP-2 using the guide screw system, we observed an approximately 90% inhibition of tumor growth as compared to the controls. Furthermore, the Ad-MMP-2-treated animals did not exhibit any neurological or other symptoms for the duration of the study. In another, separate experiment, Ad-MMP-2-infected U-251 cells, when injected intracerebrally, failed to develop intracranial tumors in nude mice after 6 weeks (data not shown), thereby highlighting the early involvement of the molecule in tumor evolution. Similarly, previous studies have demonstrated that adenovirus-mediated delivery of MMP-2 siRNA suppressed tumor growth and lung metastasis in mice (Chetty et al., 2006) .
The results of the present study and previous data support the concept of developing cancer therapies that specifically target different proteinases. Recent data show a correlation between the enhanced expression of MMP-2 in irradiated glioblastoma cells and subsequent increased invasion both in vitro and in vivo (Wild-Bode et al., 2001; Park et al., 2006) . However, the results of clinical trials using synthetic inhibitors of MMPs have been rather disappointing and several explanations for this outcome have been proposed (Coussens et al., 2002) . As long as the barriers of delivery are overcome, and efficient, safe vectors and methods of transfer are developed, the specific inhibition of MMPs, via siRNA, might prove more beneficial. Also, taking into consideration the early involvement of MMPs in tumor evolution, such therapies may be more efficient when induced in an earlier stage of the disease and possibly in combination with other traditional or newly developed strategies against brain cancer.
Materials and methods
Cell cultures and adenoviral constructs
Glioblastoma cell lines U-87 and U-251 were grown in Dulbecco's modified Eagle's medium. Cultures were supplemented with 1% glutamine, 100 mg/ml streptomycin, 100 U/ml penicillin and 10% fetal bovine serum and maintained in a humidified atmosphere containing 5% CO 2 at 37 1C. The adenoviral constructs carrying siRNA against MMP-2 (Ad-MMP-2) and a scrambled MMP-2 sequence (Ad-SV) were designed and constructed as previously described (Chetty et al., 2006) . Briefly, the following siRNA sequences were cloned into the pSuppressor vector: 5 0 -AACGGACAAAGAGTTGGCAGTATCGATACTGC CAACTCTTTGTCCGTT for Ad-MMP-2 and 5 0 -GCACG GAGGTTGCAAAGAATAATCGATTATTCTTTGCAACC TCCGTGC for Ad-SV.
We used the adenoviral pSuppressor kit (Imgenex, San Diego, CA, USA) to create the final constructs as per the manufacturer's instructions. The pSuppressor plasmids were digested with PacI and co-transfected with pAd vector backbone in 293 cells for recombinant generation of the adenoviruses carrying MMP-2 siRNA and the scrambled sequence. Viruses were plaque purified and used to infect 293 cells, and subsequently purified on a cesium chloride gradient and tittered as previously described (Chetty et al., 2006) .
Gelatin zymography
Cells were infected with mock, Ad-SV (100 MOIs) or Ad-MMP-2 (10, 25, 50 and 100 MOIs). At 48 h after infection, conditioned medium was replaced with serum-free medium, and cells were incubated overnight. Each sample (30 mg) was assayed for gelatinase activity as previously described (Sawaya et al., 1998) . Briefly, electrophoresis was performed on 10% SDS-polyacrylamide gel electrophoresis (PAGE) containing 1 mg/ml gelatin. Gels were washed in 2.5% Triton X-100 and incubated overnight at 37 1C in a buffer (50 mmol/l Tris-HCl, 0.05% NaN 3 , 5 mmol/l CaCl 2 and 1 mmol/l ZnCl 2 , pH 7.6). Gels were stained with Amido black solution, destained and MMP-2 activity was visualized as clear bands on a dark background.
Western blot analysis U-87 and U-251 cells were mock infected or infected with the indicated MOIs of Ad-SV and Ad-MMP-2. Equal amounts of total protein from conditioned media or cell lysates obtained by lysing cells in a suitable buffer (50 mmol/l Tris-HCl (pH 8.0), 150 mmol/l NaCl, 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 0.5 mmol/l phenylmethylsulfonylfluoride) were separated on SDS-PAGE and transferred to polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA, USA). After blocking with 6% nonfat milk and 0.1% Tween-20 in Trisbuffered saline, membranes were incubated with anti-MMP-2 (Chemicon, Temecula, CA, USA)), anti-VEGF (Biomeda, Foster City, CA, USA), anti-caspase-3, anti-caspase-9 (Santa Cruz, Santa Cruz, CA, USA) or anti-caspase-8 (Cell Signaling, Danvers, MA, USA) antibodies, followed by incubation with horseradish peroxidase (HRP)-conjugated anti-mouse or antirabbit secondary antibody. Membranes were developed using the ECL system (Amersham Bioscience, Piscataway, NJ, USA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody was used as a loading control.
Cell proliferation assay
Cell growth was assessed by MTT assay. To detect the effect of these constructs on the growth of the U-87 and U-251 cells in vitro, we measured viable cell mass using the Cell Titer 96 colorimetric assay as previously described by our group (Gondi et al., 2004b) .
Immunofluorescence U-87 and U-251 cells were cultured in eight-well chamber slides (10 000 cells per well) and infected with mock, 100 MOIs of Ad-SV, or 25, 50 and 100 MOIs of Ad-MMP-2. After 72 h, cells were fixed in cold methanol and incubated with 0.1% Triton X-100 in PBS. Then, cells were blocked with 3% bovine serum albumin (BSA) for 1 h and incubated with mouse anti-MMP-2 in 1% BSA in PBS (dilution 1:500). Cells were washed with PBS and mouse fluorescein isothiocyanate (FITC)-conjugated secondary antibody was added for 1 h. Finally, slides were washed with PBS, mounted and examined under a fluorescent microscope connected to an Olympus camera.
Matrigel invasion assay U-87 or U-251 cells infected with mock or adenoviral constructs (100 MOIs of Ad-SV, 50 and 100 MOIs of Ad-MMP-2) were trypsinized, counted, and 2 Â 10 5 cells were placed in matrigel-coated transwell inserts (8-mm pores). Cells were allowed to invade through the matrigel for 48 h. Then, cells in the upper chamber were removed by cotton swab. Cells adhered on the outer surface that had invaded through the matrigel were fixed, stained with Hema and counted under a light microscope as previously described (Lakka et al., 2002) .
Spheroid migration assay U-87 or U-251 cells stably transfected with a green fluorescent protein (GFP)-expressing plasmid (4 Â 10 4 ) were seeded in 96-well plates coated with 1% agarose in PBS and cultured on a shaker at 90 r.p.m. for 48 h. After single spheroids formed, cells were infected with mock, 100 MOIs of Ad-SV or 50 and 100 MOIs of Ad-MMP-2. After 24 h, spheroids were transferred to eight-well chamber slides and were allowed to grow for 48 h. The results were observed under a confocal scanning laser microscope and the migration distance was measured using Image Pro Discovery software as described previously (Lakka et al., 2005a) .
In vitro angiogenesis assay (conditioned media) Human microvascular endothelial cells (HMECs) (4 Â 10 4 ) were seeded in eight-well chamber slides. The next day, conditioned medium was replaced with the media collected from cell cultures of U-87 or U-251 infected with mock, 100 MOIs of Ad-SV or 50 and 100 MOIs of Ad-MMP-2. Fresh conditioned media from the tumor cell cultures were added daily to the endothelial cells. The endothelial cells were incubated for 72 h, fixed and stained with H&E. The angiogenic result was measured by counting the relative branch points in each field as described previously (Gondi et al., 2004a) .
In vitro angiogenesis assay (co-culture) U-87 or U-251 cells (7 Â 10 3 per well) were plated in eight-well chamber slides and infected with mock, 100 MOIs of Ad-SV or 50 and 100 MOIs of Ad-MMP-2. After 24 h, conditioned media was removed and HMECs (4 Â 10 4 ) were seeded and allowed to co-culture for 48 h. Then, cells were fixed with cold methanol and blocked with 3% BSA in PBS. Cells were incubated with Factor-VIII antibody (Dako Corp., Carpinteria, CA, USA), washed with PBS, incubated with FITC-conjugated secondary antibody and finally washed with PBS. The angiogenic result was examined under a confocal scanning laser microscope and quantified by counting the relative branch points in each field.
In vivo angiogenesis (dorsal skin-fold chamber model) U-87 cells were infected with mock, 100 MOIs of Ad-SV or 50 and 100 MOIs of Ad-MMP-2. After 24 h, cells were trypsinized, and cells were suspended in 100 ml serum-free media (1 Â 10 6 cells) and injected into diffusion chambers through the opening of the 'O' ring (Fisher, Pittsburg, PA, USA), which was then sealed with bone wax. The chambers were prepared by aligning 0.45 mm Millipore membranes (Fisher, Pittsburg, PA, USA) on both sides of the 'O' ring with sealant. The chambers were sterilized by UV radiation. Athymic female mice, 6-9 weeks old (five per group) were anesthetized by intraperitoneal injection with ketamine 50 mg/kg and xylazine 10 mg/kg. A dorsal air sac was created by subcutaneously injecting 5 ml of air. Then, a superficial incision was made at the edge of the air sac, through which, the chambers were placed carefully underneath the skin. After 10 days, the animals were anesthetized, killed and the skin area covering the chambers was removed and photographed under visible light. The number of blood vessels and their length in the skin fold was examined as previously described (Lakka et al., 2005a) .
TUNEL assay U-87 and U-251 cells were infected with mock, Ad-SV (100 MOIs) or Ad-MMP-2 (50 and 100 MOIs) in eight-well chamber slides for 3 days. Then, terminal deoxynucleotidyl transferase biotin-dUTP nick end-labeling (TUNEL) assay was performed using an apoptosis detection kit (Upstate Cell Signaling (Millipore, Billerica, MA, USA) according to the manufacturer's instructions. Briefly, cells were fixed with 4% paraformaldehyde and incubated with 0.5% Tween-20, 0.2% BSA in PBS for 15 min at room temperature. Cells were washed with PBS and incubated with terminal deoxynucleotidyl transferase end-labeling cocktail for 60 min. The reaction was stopped with Tris-borate buffer, cells were washed and incubated for 30 min in the dark with avidin-FITC solution diluted in the provided blocking buffer. Finally, cells were washed, mounted and photographed under a fluorescent microscope.
Electrophoresis of total nuclear DNA Total nuclear DNA was purified from U-87 and U-251 cells, which were infected with mock or the adenoviral constructs Ad-SV and Ad-MMP-2, and electrophoretically separated on a 1% agarose gel stained with ethidium bromide. The gel was exposed to UV light, photographed and analyzed for DNA fragmentation.
Animal studies U-251 glioblastoma cells, stably transfected with a luciferinexpressing plasmid, were grown in serum-containing culture media. Cells were trypsinized and were resuspended in PBS and injected 10 ml (1 Â 10 6 cells) intracerebrally into nude mice through the channel of a guide screw system as previously described (Lal et al., 2000) . A cross-shaped stylet was fitted within the screw to prevent cells tissue from growing into the screw hole. Tumors were allowed to grow for 8 days before animals received three separate treatments at 5-day intervals through the screw system. Animals were separated into three groups (eight animals per group) and were treated intratumorally. Each treatment involved the administration of either 10 ml of PBS (mock) or 3 Â 10 8 PFUs of Ad-SV or Ad-MMP-2 diluted in 10 ml of PBS. After animals received an intraperitoneal injection of 2.5 mg of D-luciferin sodium salt (Gold Bio Technology, St Louis, MO, USA) diluted in 50 ml of PBS, tumor volume and growth were monitored using a IVIS-200 Xenogen imaging system (Xenogen Corporation, CA, USA). The camera was connected to software (IVIS) that expresses the amount of the fluorescent light emission from the tumors as photon counts. After 6 weeks and/or when the control animals started showing symptoms, animals were anesthetized and killed by intracardiac perfusion of PBS followed by formaldehyde. The brains were removed and sections were stained with H&E to visualize tumor cells and to examine tumor volume. For the immunohistochemical experiments, brain sections were deparaffinized in xylene and rehydrated through graded alcohol. Then, slides were incubated with 0.1% Triton X-100, blocked with 3% BSA in PBS and incubated with anti-MMP-2, anti-VEGF (Santa Cruz, Santa Cruz, CA, USA), anti-GFAP(1:100 dilution) or anti-endoglin (CD105) (Dako Corp., Denmark) (1:20 dilution). After a rinse in PBS, slides were incubated with HRP-conjugated secondary antibody for 1 h at a dilution of 1:300, washed again with PBS and incubated with 0.05% 3,3 0 -diaminobenzidine as chromogen. Finally, slides were counterstained with hematoxylin, mounted and observed under a light microscope.
Statistical analysis
All data are presented as means ± standard errors (s.e.) of at least three independent experiments, each performed at least in triplicate. Results were analysed using a two-tailed Student's t-test to assess statistical significance. Statistical differences are presented at probability levels of Po0.05 and Po0.01.
